west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "卞兆祥" 41 results
  • Randomized Controlled Pragmatic Trial: Concept, Design, Practice

    The two factors that affect enrollment of participants and the process of intervention in randomizedcontrolled pragmatic trials are similar to the situation of clinical practice, thus its effects are similar to the situation ofclinical practice. Therefore, when one estimates an intervention’s effect on a patient, it will be more similar to a real clinicalsituation than results taken from an explanatory trial. Due to the introduction of interventions and process variables usedin a pragmatic trial that conform to traditional Chinese medicine and acupuncture practices, more and more interest isgrowing among researchers in the traditional Chinese medicine field. This article introduces the principles and conceptsof the pragmatic trial, and the key points of design via some samples.

    Release date:2016-08-25 03:36 Export PDF Favorites Scan
  • Promoting standardization of clinical trial data management in China

    Data management system is a major factor affecting the quality of clinical trial. Development of data management system include a steering group and data safety and monitoring board, data collection, database, performance of the data safety and monitoring, as well as locking of database. This article provides key issues of the five parts so as to help researchers understand the clinical trial data management system.

    Release date:2018-06-20 02:05 Export PDF Favorites Scan
  • Further improve the reporting quality of clinical research in China

    Release date:2021-01-26 04:48 Export PDF Favorites Scan
  • Changing face: from the publication of CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration to changing of clinical trials in China

    Release date:2017-09-15 11:24 Export PDF Favorites Scan
  • Strengthen the process report of clinical trials, promote full transparency of clinical trials

    The concept of clinical trial transparency has been promoted for more than 40 years. The act of clinical trial registration, report guidelines development, and data sharing has has been strongly pushed forward and become a common practice. The clinical trial process being the key procedure of trial operation and quality control, determines the accuracy of the results. However, the process report of clinical trials is insufficient. In this article, we summarize the importance of clinical trial process report and provide corresponding suggestions. We propose that medical journals, reporting guidelines developers and clinical trial registration platforms should work together to strengthen the process report of clinical trials and promote full transparency of clinical trials.

    Release date:2018-07-18 02:49 Export PDF Favorites Scan
  • Developing design, implementation and reporting guidelines for multi-center clinical trials is imperative

    With the encouragement of national policy on drug and medical device innovation, multi-center clinical trials and multi-regional clinical trials are facing an unprecedented opportunity in China. Trials with a multi-center design are far more common at present than before. However, it should be recognized there still exists shortcomings in current multi-center trials. In this paper, we summarize the problems and challenges and provide corresponding resolutions with the aim to reduce heterogeneity between study centers and avoid excessive center effects in treatment. It is urgent to develop design, implementation and reporting guidelines to improve the overall quality of multi-center clinical trials.

    Release date:2018-07-18 02:49 Export PDF Favorites Scan
  • Transparency and sharing individual participant data of clinical trials: a philosophical proposition about the medical study ethics and implications for clinical trials

    Clinical trial transparency, include clinical trial registration, unbiased reporting results and sharing individual participant data (IPD), is one of the most important revolutionary concepts following clinical epidemiology and evidence-based medicine in the medical field. Sharing IPD is a medical ethics issue reflected a new sense of worth and constructing new rules of clinical trials. Our viewpoint is that from the essential purpose of clinical research, IPD is a social public property. Sharing IPD is a one of the best ways for respecting the contributions of the participants, and one of the keys for changing face of clinical trials.

    Release date:2018-06-20 02:05 Export PDF Favorites Scan
  • Review of Adverse Reactions to Chinese Medicine Injections△

    Using Chinese Materia Medica (CM) as injections is an innovation that is proving effective in extensive clinical use in Mainland China. However, recent reports have focused on adverse reactions, ignoring the considerable successes of these preparations. In order to achieve balance in the media and in the minds of the public, we suggest the first step is to clarify the concepts of and differences between adverse drug reactions (ADR) and adverse events (AE) for all concerned—the public, medical practitioners, government officials, and lawmakers. Second, the State Food and Drug Administration should raise the requirements for Chinese Medicine Injection (CMI) registration and license approval and emphasize the importance of evidence-based CMI development and evidence-based CMI license approval. Thirdly, drug companies and institutions should reinforce basic research about the quality control of herbs and CMI-drug interactions. Fourth, the Government should clarify the legal responsibilities for CMI approval agencies, CMI developers, medical doctors, and patients. Fifth, the medical association and Government should enhance training for health care professionals concerning the usage of CMIs. And finally sixth, State Food and Drug Administration should monitor the content and quality of the directions for use of CMI.

    Release date:2016-09-07 11:13 Export PDF Favorites Scan
  • Reporting guideline for health care simulation research: extensions to the CONSORT and STROBE statements

    背景 基于仿真研究(simulation-based research,SBR)的数量迅速增加,但是这类研究的报告质量却需亟待提高。为使读者能够批判性地评估研究,研究报告的要素需要在文章中清晰地报告出来。我们旨在通过扩展试验报告的统一标准(Consolidated Standards of Reporting Trial,CONSORT)和加强流行病学观察性研究报告(Strengthening the Reporting of Observational Studies in Epidemiology,STROBE)声明来制定卫生保健仿真研究的报告规范。 方法 在制定报告规范的建议步骤基础上,使用迭代的多步共识法建立流程。多步共识法包括以下内容:① 建立指导委员会;② 定义报告规范的范围;③ 确定共识小组参与者;④ 通过在线会前调查生成拟讨论项目清单;⑤ 召开共识会议;⑥ 起草报告规范及解释与说明文件。 结果 对 CONSORT 的 11 个条目进行了扩展,包括条目 1(文题和摘要),条目 2(背景),条目 5(干预措施),条目 6(结局指标),条目 11(盲法),条目 12(统计方法),条目 15(基线数据),条目 17(结果和估计值),条目 20(局限性),条目 21(可推广性)和条目 25(资金来源)。对 STROBE 的 10 个条目进行了扩展:条目 1(文题和摘要),条目 2(背景/原理),条目 7(变量),条目 8(数据来源/数据测量),条目 12(统计方法),条目 14(描述性数据),条目 16(主要结果),条目 19(局限性),条目 21(可推广性)和条目 22(资金来源)。工作组已创建详细说明文档,提供每个扩展条目的示例和说明。 结论 制订基于 CONSORT 和 STROBE 声明的仿真研究扩展版,可帮助提高仿真研究的报告质量。

    Release date:2021-03-19 07:04 Export PDF Favorites Scan
  • Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension

    背景 随机对照试验(randomized controlled trials,RCTs)常用于评估社会和心理干预措施的效果,这些结果亦常被用于制定决策。有关社会及心理干预措施试验结果的准确、完整和透明的报告,对了解针对这些干预措施的临床试验设计、实施、结果及这些结果的应用至关重要。然而,关于社会和心理干预措施的 RCT 报告质量仍不理想。CONSORT(consolidated standards of reporting trials)声明改善了生物医学领域 RCT 的报告质量,同样,行为和社会科学方面也需要类似的高质量报告规范。我们的目标是基于 RCT 报告规范 2010 年声明(Consolidated Standards of Reporting Trials 2010 Statement,CONSORT 2010)的官方扩展版,制定适用于社会和心理干预措施(social and psychological interventions,SPI)的 RCT 报告规范(CONSORT-SPI 2018)。 方法 我们遵循最佳方案制定报告规范的扩展版。首先,我们对现有报告规范进行了系统评价。随后,我们进行了有 384 位国际参与者参加的德尔菲在线调查。2014 年 3 月,我们举行了为期 3 天的共识会议,由 31 位专家参与,确定针对社会和心理干预措施的 RCT 报告的检查清单内容。专家们仔细讨论了先前与社会和心理干预措施 RCT 相关的研究和方法学问题。然后,投票决定对 CONSORT 2010 条目的修改或扩展。 结果 CONSORT-SPI 2018 检查清单扩展了 CONSORT 2010 的 25 个条目中的 9 个,包括:背景和目标、试验设计、受试者、干预措施、统计方法、受试者流程、基线数据、结果和估计及资助来源。此外,与会者还添加了一个与利益相关方参与度有关的新条目,此外,也修改了与受试者招募和及其后续维持相关的流程图。 结论 作者应使用 CONSORT-SPI 2018 来改善社会和心理干预相关的 RCT 的报告质量。期刊应修改编辑政策和程序,要求作者使用报告规范准备相关稿件,要求同行评议者使用报告规范评审相关稿件,以使读者能够评估研究的质量,评价研究结果的推广性,并重复有效的干预措施。

    Release date:2021-01-26 04:48 Export PDF Favorites Scan
5 pages Previous 1 2 3 4 5 Next

Format

Content